

Profiles

February 18, 2016

## **Charles M. Beasley, Jr., M.D.**

### **Publications – 29-December 2015**

#### **PATENTS ISSUED**

- 5605897 2-Methyl-Thieno-Benzodiazepine (Olanzapine)
- 5817656 Method for Treating Mental Disorders (Olanzapine)
- 5817657 Method for Treating Psychoactive Substance Disorders (Olanzapine)
- 5776928 Method for Treating Dyskinesia (Olanzapine)
- 6071902 Method for Treating Excessive Aggression (Olanzapine)
- 6159963 Method for Treating Substance Abuse (Olanzapine)
- 6274636 Method of Treating Tic Disorder (Olanzapine)
- 6506746 Method for Treating Cognitive Dysfunction (Olanzapine)

#### **BOOK CHAPTERS**

1. Beasley C, Grundy S, Gannon K, Berg P  
**Overview of the safety of olanzapine**  
In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)  
*Olanzapine (Zyprexa): A Novel Antipsychotic*  
Philadelphia: Lippincott Williams & Wilkins, 2000.
2. Tran P, Sutton V, Beasley C, Tollefson G  
**Efficacy of olanzapine**  
In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)  
*Olanzapine (Zyprexa): A Novel Antipsychotic*  
Philadelphia: Lippincott Williams & Wilkins, 2000.
3. Anderson J, Kline P, Beasley C  
**A general learning theory and its application to schema abstraction**  
In Bower G (Ed.)  
*The Psychology of Learning and Motivation, Vol 13.*  
New York: Academic Press, 1979.
4. Anderson J, Kline P, Beasley C  
**Complex learning processes**  
In Snow R, Federico P & Montague W (Eds.)

*Aptitude, Learning, and Instruction, Vol 2: Cognitive Process Analysis of Learning and Problem Solving*  
Hillsdale, NJ: Lawrence Erlbaum and Associates, 1980.

## ARTICLES

1. Crowe B, Brueckner A, Beasley C, Kulkarni P  
**Current practices, challenges, and statistical issues with product safety labeling**  
*Statistics in Biopharmaceutical Research* 5:180-193; 2013.
2. Loghin C, Haber H, Beasley CM, Kothare PA, Kauffman L, April J, jin L, Allen AJ, Mitchell MI  
**Effect of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers**  
*Br J Clin Pharmacol* 75:549-564; 2013.
3. Beasley C, Benson C, Xia J, Young S, Haber H, Mitchell M, Loghin C  
**Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions**  
*PACE* 34:1116-1127; 2011.
4. Millen BA, Campbell GM, Beasley CM  
**Weight changes over time in adults treated with oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials**  
*J Psychopharmacol* 25:639-645; 2011.
5. Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV  
**Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target for for drug development: a brief report**  
*J Clin Psychiatry* 71:1040-1046; 2010.
6. Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV  
**Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target for for drug development: a consensus statement**  
*J Clin Psychiatry* 71:pe1-pe21; 2010.
7. Lipkovich I, Jacobson JG, Caldwell C, Hoffman VP, Kryzhanovskaya L, Beasley CM  
**Early predictors of weight gain risk during treatmentwith olanzapine: analysis of pooled data from 58 clinical trials**  
*Psychopharm Bull* 42:23-39; 2009.
8. Beasley CM, Dmitrienko A, Mitchell MI  
**Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead)**

### ECG recordings

*Expert Rev Clin Pharmacol* 1:815-839; 2008.

9. Beasley C, Ball S, Nilsson M, et al

**Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials**

*J Clin Psychopharmacol* 27:682-686; 2007.

10. Tauscher-Wisniewski S, Disch, Plewes J, Ball SG, Beasley CM

**Evaluating suicidality as an adverse event in clinical trials of fluoxetine treatment for indications other than major depressive disorder**

*Psychol Med* 37:1-9; 2007.

11. Beasley CM, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM,

**All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis**

*J Clin Psychopharmacol* 27:252-258; 2007.

12. Perlis RH, Beasley CM, Wines JD, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F, Strong RE, Rosenbaum JF, Fava M

**Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes**

*Psychother Psychosom* 76:40-46; 2007.

13. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM, Rosenbaum JF, Perlis RH

**Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications**

*J Clin Psych* 68:52-57; 2007.

14. Crumb WJ, Ekins S, Darazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM

**Effects of Antipsychotic Drugs on I<sub>to</sub>, I<sub>Na</sub>, I<sub>sus</sub>, I<sub>K1</sub>, and hERG: QT prolongation, atructure activity relationship and network analysis**

*Pharmacol Res* 23:1133-1143; 2006.

15. Beasley CM, Sutton VK, Taylor CC, Sethuraman G, Dossenbach M, Naber D

**Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?**

*J Clin Psychopharmacol* 26:40-44; 2006.

16. Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, Whitaker JS, Beasley CM

**Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial**

*J Sexual Med* 2:685-698; 2005.

17. Beasley CM, Mitchell MI, Dmitrienko AA, Emmick JT, Shen W, Costigan TM, Bedding AW, Turick MA, Bakhtyari A, Warner MR, Ruskin JN, Cantilena LR, Kloner RA

**The combined use of ibutilide as an active control with intensive ECG sampling and signal averaging as a sensitive method to assess the effects of talafil on the human QT interval**

*J Am Coll Cardiol* 46:678-687; 2005.

18. Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM, Hague JA, Ahuja S  
**Tadalafil improved erectile function at 24 and 36 hours after dosing: US trial**  
*J of Andrology* 26:310-318; 2005.
19. Sarazan RD, Crumb WJ, Beasley CM, Emmick JT, Ferguson KM, Strnat CA, Sausen PJ  
**Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5 – sildenafil, tadalafil, and vardenafil**  
*E J Pharmacology* 502:163-167; 2004.
20. Von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, Lockhart D, Beasley C, Emmick J  
**A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil**  
*Eu Urology* 45:499-507; 2004.
21. Beasley C, Sutton V, Hamilton S, Walker D, Dossenbach M, Taylor C, Alaka K, Bykowski D, Tollefson G  
**A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse**  
*J Clin Psychopharmacol* 23:582-594; 2003.
22. Helstrom WJG, Overstreet JW, Yu A, Saikali K, Shen W, Beasley, CM, Watkins VS  
**Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones**  
*J Urology* 170:887-891; 2003.
23. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM  
**An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine**  
*J Clin Psychiatry* 64:898-906; 2003.
24. Lindborg S, Beasley C, Alaka K, Taylor C  
**Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients**  
*Psychiatry Res* 119:113-123; 2003.
25. Quitkin F, Petkova E, McGrath P, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M, Rosenbaum J, Reimherr F, Fawcett J, Chen Y, Klein D  
**When should a trial of fluoxetine for major depression be declared failed?**  
*Am J Psychiatry* 160:734-740; 2003.

26. Inada T, Beasley C, Tanaka Y, Walker D  
**Extrapyramidal symptom profiles assessed with DIEPSS: comparison with western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol**  
*Intl Clin Psychopharmacol* 18:39-48; 2003.
27. Sowell M, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg H, Breier, Breier A, Beasley C, Dananberg J  
**Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or olanzapine**  
*J Clin Endocrinology and Metab* 87:2918-2923; 2002.
28. Meehan K, Wang H, David S, Nisivoccia J, Jones B, Beasley C, Feldman P, Mintzer J, Beckett L, Breier A  
**Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia**  
*Neuropsychopharmacology* 26:494-504; 2002.
29. Brunswick D, Amsterdeam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C  
**Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment**  
*J Affect Diord* 68:243-249; 2002.
30. Kennedy J, Bymaster F, Schuh L, Calligaro D, Nomikos G, Felder C, Bernauer B, Kinon B, Baker R, Hau D, Roth H, Dossenbach M, Kaiser C, Beasley C, Holcombe J, Effron M, Breier A  
**A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data**  
*Int J Geriatr Psychiatry* 16:S33-S61; 2001.
31. Brunswick D, Amsterdeam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C  
**Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy**  
*J Clin Psychopharmacol* 21:616-618; 2001.
32. Czekalla J, Beasley C, Dellva M, Berg P, Grundy S  
**Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis**  
*J Clin Psychiatry* 62:191-198; 2001.
33. Czekalla J, Kollack-Walker S, Beasley C  
**Cardiac Safety Parameters of Olanzapine: comparison with other atypical and typical antipsychotics**  
*J Clin Psychiatry* 62:suppl 2:35-40; 2001.

34. Czekalla J, Beasley CM, Ditmann RW, Helsberg K, Kollack-Walker S  
**Kardiale verträglichkeit unter nueroleptika: vergleichende übersicht zu Qtc-parametern und assoziierten effekten unter olanzapin und anderen atypischen sowie typischen antipsychotika**  
*Nervenheilkunde* 20:194-201; 2001
35. Perry P, Lund B, Sanger T, Beasley C  
**Olanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine trial**  
*J Clin Psychopharmacol* 21:14-20; 2001.
36. Beasley C, Koke S, Nilsson M, Gonzales J  
**Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis**  
*Clin Ther* 22:1319-1330; 2000.
37. Voss S, Sanger T, Beasley C  
**Hematologic reference ranges in a population of patients with schizophrenia**  
*J Clin Psychopharmacol* 20:653-657, 2000.
38. Beasley C, Nilsson M, Koke S, Gonzales J  
**Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose**  
*J Clin Psychiatry* 61:722-728; 2000.
39. McGrath P, Stewart J, Petkova E, Quitkin F, Amsterdam J, Fawcett J, Reimherr F, Rosenbaum J, Beasley C  
**Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression**  
*J Clin Psychiatry* 61:518-524; 2000.
40. Michelson D, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Zajecka J, Sundell K, Kim Y, Beasley C  
**Changes in Weight During a 1-Year Trial of Fluoxetine**  
*Am J Psychiatry* 156:1170-1176; 1999.
41. Revicki D, Genduso L, Hamilton S, Ganoczy D, Beasley C  
**Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial**  
*Qual Life Res* 8:417-426; 1999.
42. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C  
**Fluoxetine efficacy in menopausal women with and without estrogen replacement**  
*J Affect Disord* 55:11-17; 1999.
43. Callaghan J, Bergstrom R, Ptak L, Beasley C  
**Olanzapine: pharmacokinetic and pharmacodynamic profile**  
*Clin Pharmacokinet* 37:177-193; 1999.

44. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C  
**Blood pressure changes during short-term fluoxetine treatment**  
*J Clin Psychopharmacol* 19:9-14; 1999.
45. Zajecka J, Amsterdam J, Quitkin F, Reimberr F, Rosenbaum J, Tamura R, Sundell K, Michelson D, Beasley C  
**Changes in adverse events reported by patients during 6 months of fluoxetine therapy**  
*J Clin Psychiatry* 60:389-394; 1999.
46. Beasley C, Dellva M, Tamura R, Morgenstern H, Glazer W, Ferguson K, Tollefson G  
**Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol**  
*Br J Psychiatry* 174:23-30; 1999.
47. Tran P, Tollefson G, Sanger T, Lu Y, Berg P, Beasley C  
**Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy**  
*Br J Psychiatry* 174:15-22; 1999.
48. Sanger T, Lieberman J, Tohen M, Grundy S, Beasley C, Tollefson G  
**Olanzapine versus haloperidol treatment in first episode psychosis**  
*Am J Psychiatry* 156:79-87; 1999.
49. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Schweizer E, Beasley C  
**Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode**  
*J Clin Psychopharmacol* 18:435-440; 1998.
50. Reimherr F, Amsterdam J, Qutikin F, Rosenbaum J, Fava M, Zajecka J, Beasley C, Michelson D, Roback P, Sundell K  
**Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment**  
*Am J Psychiatry* 155:1247-1253; 1998.
51. Beasley C  
**Olanzapine: recent clinical findings and increased patient benefits**  
*Japanese J Clin Psychopharmacol* 1:759-765; 1998.



52. Tollefson G, Sanger T, Beasley C, Tran P  
**A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia**  
*Biol Psychiatry* 43:803-810; 1998.
53. Tran P, Dellva M, Tollefson G, Wentley A, Beasley C  
**Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses**  
*Br J Psychiatry* 172:499-505; 1998.
54. Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Beasley C  
**Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study**  
*J Clin Psychopharmacol* 18:193-197; 1998.
55. Stewart J, Quitkin F, McGrath P, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P  
**Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo**  
*Arch Gen Psychiatry* 55:334-343; 1998.
56. Hamilton S, Revicki D, Genduso L, Beasley C  
**Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind Trial**  
*Neuropsychopharmacology* 18:41-49; 1998.
57. Perry P, Sanger T, Beasley C  
**Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients**  
*J Clin Psychopharmacol* 17:472-477; 1997.
58. Dellva M, Tran P, Tollefson G, Wentley A, Beasley C  
**Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia**  
*Psychiatric Services* 48:1571-1577; 1997.
59. Goldstein D, Hamilton S, Masica D, Beasley C  
**Fluoxetine in Medically Stable, Depressed Geriatric Patients: Effects on Weight**  
*J Clin Psychopharmacol* 17:365-369; 1997.
60. Crawford A, Beasley C, Tollefson G  
**The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations**  
*Schizophrenia Res* 26:41-54; 1997.
61. Tran P, Hamilton S, Kuntz A, Potvin J, Andersen S, Beasley C, Tollefson G  
**Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and**

**other psychotic disorders**

*J Clin Psychopharmacol* 17:407-418; 1997.

62. Tollefson G, Beasley C, Tamura R, Tran P, Potvin J

**Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol**

*Am J Psychiatry* 154:1248-1254; 1997.

63. Beasley C, Tollefson G, Tran P

**Safety of olanzapine**

*J Clin Psychiatry* 58:Suppl 10:13-17; 1997.

64. Beasley C, Tollefson G, Tran P

**Efficacy of olanzapine: an overview of pivotal clinical trials**

*J Clin Psychiatry* 58:Suppl 10:7-12; 1997.

65. Blumenfield M, Levy N, Spinowitz B, Charytan C, Beasley C, Dubey A, Solomon R, Todd R, Goodman A, Bergstrom R

**Fluoxetine in depressed patients on dialysis**

*Intl J Psychiatry in Medicine* 27:71-80; 1997.

66. Beasley C, Hamilton S, Crawford A, Dellva M, Tollefson G, Tran P, Blin O, Beuzen J

**Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial**

*Euro Neuropsychopharmacol* 7:125-137; 1997.

67. Amsterdam J, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Hornig-Rohan M, Beasley C

**Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study**

*Am J Psychiatry* 154:963-969; 1997.

68. Tran P, Dellva M, Tollefson G, Beasley C, Potvin J, Kiesler G

**Extrapyramidal Symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia**

*J Clin Psychiatry* 58:205-211; 1997.

69. Tollefson G, Beasley C, Tran P, Street J, Kruger J, Tamura R, Graffeo K, Thieme M

**Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial**

*Am J Psychiatry* 154:457-465; 1997.

70. Beasley C

**Safety of olanzapine**

*J Clin Psychiatry Monograph* 15:2:19-21; 1997.

71. Beasley C

**Efficacy of olanzapine**

*J Clin Psychiatry Monograph* 15:2:17-19; 1997.

72. Levy N, Blumenfield M, Beasley C, Dubey A, Solomon R, Todd R, Goodman A, Bergstrom R  
**Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function**  
*Gen Hosp Psychiatry* 18:8-13; 1996.
73. Beasley C, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S  
**Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial**  
*Psychopharmacology* 124:159-167; 1996.
74. Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S  
**Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial**  
*Neuropsychopharmacol* 14:111-123; 1996.
75. Tollefson G, Rampey A, Beasley C, Enas G, Potvin J  
**Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression**  
*J Clin Psychopharmacol* 14:163-169; 1994.
76. Tollefson G, Fawcett J, Winokur G, Beasley C, Potvin J, Faries D, Rampey A, Sayler M  
**Evaluation of suicidality during pharmacologic treatment of mood and non-mood disorders**  
*Ann Clin Psychiatry* 5:209-224; 1993.
77. Beasley C, Holman S, Potvin J  
**Fluoxetine compared with imipramine in the treatment of inpatient depression : a multicenter trial**  
*Ann Clin Psychiatry* 5:199-207; 1993.
78. Beasley C, Sayler M, Potvin J  
**Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial**  
*Intl Clin Psychopharmacol* 8:143-149; 1993.
79. Heiligenstein J, Beasley C, Potvin J  
**Fluoxetine not associated with increased aggression in controlled clinical trials**  
*Intl Clin Psychopharmacol* 8:277-280; 1993.
80. Beasley C, Potvin J  
**Fluoxetine: activating and sedating effects**  
*Intl Clin Psychopharmacol* 8:271-275; 1993.
81. Bergstrom R, Beasley C, Levy N, Blumenfield M, Lemberger L  
**A review of the effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and their risk-benefit profile of fluoxetine**  
*Intl Clin Psychopharmacology* 8:261-266; 1993.
82. Beasley C, Masica D, Heiligenstein J, Wheadon D, Zerbe R  
**Possible monoamine oxidase inhibitor – serotonin uptake inhibitor interaction: fluoxetine clinical**

**data and preclinical findings.**

*J Clin Psychopharmacol* 13:312-320; 1993

83. Goldstein D, Rampey A, Potvin J, Masica D, Beasley C

**Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction**

*J Clin Psychiatry* 54:309-316; 1993.

84. Heiligenstien J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D

**Fluoxetine not associated with increased violence or aggression in controlled clinical trials**

*Ann Clin Psychiatry* 4:285-295; 1992.

85. Beasley C, Sayler M, Weiss A, Potvin J

**Fluoxetine: activating and sedating effects at multiple fixed doses**

*J Clin Psychopharmacol* 12:328-333; 1992.

86. Wheadon D, Rampey A, Thompson V, Potvin J, Masica D, Beasley C

**Lack of association between fluoxetine and suicidality in bulimia nervosa**

*J Clin Psychiatry* 53:235-241; 1992.

87. Beasley C, Dornseif B, Bosomworth J, Sayler M, Rampey A, Heiligenstein J, Thompson V, Murphy D, Masica D

**Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression**

*Intl Clin Psychopharmacol* 6:Suppl 6:53-75; 1992.

88. Beasley C, Masica D, Potvin J

**Fluoxetine: a review of receptor and functional effects and their clinical implications**

*Psychopharmacology* 107:1-10; 1992.

89. Beasley C, Potvin J, Masica D, Wheadon D, Dornseif B, Genduso L

**Fluoxetine: no association with suicidality in obsessive-compulsive disorder**

*J Affective Disorders* 24:1-10; 1992.

90. Beasley C, Dornseif B, Bosomworth J, Sayler M, Rampey A, Heiligenstien J, Thompson V, Murphy D, Masica D  
**Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression**  
*BMJ* 303:685-692; 1991.
91. Beasley C, Poltz J, Dornseif B, Bosomworth J, Sayler M  
**Fluoxetine versus trazodone: efficacy and activating-sedating effects**  
*J Clin Psychiatry* 52:294-99; 1991.
92. Beasley C, Sayler M, Bosomworth J, Wernicke J  
**High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression**  
*J Clin Psychopharmacol* 11:166-174; 1991.
93. Usher R, Beasley C, Bosomworth J  
**Efficacy and safety of morning versus evening fluoxetine administration**  
*J Clin Psychiatry* 52:134-136; 1991.
94. Beasley C, Sayler M, Cunningham G, Weiss A, Masica D  
**Fluoxetine in tricyclic refractory major depressive disorder**  
*J Affective Disorders* 20:193-200; 1990.
95. Beasley C, Bosomworth J, Wernicke J  
**Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression**  
*Psychopharm Bull* 26:18-24; 1990.
96. McCombs J, Nichol M, Stimmel G, Sclar D, Beasley C, Gross L  
**The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population**  
*J Clin Psychiatry* 51:6, suppl:60-69; 1990.
97. Beasley C, Magnusson M, Garver D  
**TSH response to TRH and haloperidol response latency in psychoses**  
*Biol Psychiatry* 24:423-31; 1988.

## LETTERS

1. Beasley C  
**Response (letter).**  
*Aust N Z J Psychiatry* 33:12-122; 1999.
2. Perry PJ, Sanger T, Beasley CM  
**Plasma olanzapine and clinical response (Response letter).**  
*J Clin Psychopharmacol* 19:193-194; 1999.
3. Beasley C  
**Response (letter).**

- Br J Psychiatry* 175:391-392; 1999.
4. Beasley C  
**Response (letter).**  
*CNS Drugs* 9:513-515; 1998.
  5. Beasley C  
**Response (letter).**  
*Neuropsychopharmacol* 16:89-90; 1997.
  6. Beasley C  
**Fluoxetine-Dopaminergic Interaction Data (letter).**  
*J Clin Psychiatry* 55:77-78; 1994.
  7. Masica D, Beasley C, Kotsanos J, Potvin J  
**Trend in suicide rates since fluoxetine introduction (letter).**  
*Am J Pub Health* 82:1295; 1992.
  8. Beasley C  
**Reply (letter).**  
*J Clin Psychopharmacol* 12:220-221; 1992.
  9. Beasley C  
**Fluoxetine and suicide (letter).**  
*BMJ* 303:1200; 1991.
  10. Fuller R, Beasley C  
**Fluoxetine: mechanism of action (letter).**  
*J Am Acad Child Adolesc Psychiatry* 30:849-850; 1991.
  11. Beasley C  
**Correction to 'Fluoxetine Overdose: A Case Report' (letter).**  
*J Anal Tox* 14:63; 1990.

#### **PUBLISHED ABSTRACTS**

1. Camporeale A, Beasley C, Tanaka Y, D'Souza D, Upadhyaya H  
**Changes in blood pressure and heart rate associated with atomoxetine treatment in attention-deficit/hyperactivity disorder**  
*Euro Neuropsychopharmacol* 22:429-430; 2012.

2. Beasley CM, Disch D, Prabhakar V, Desiah D, Tamura R, Perlis R  
**Potential predictive factors for development of treatment-emergent suicidal ideation in the fluoxetine placebo-controlled major depressive disorder database**  
*Neuropsychopharmacol* 31:S1:100-101; 2006.
3. Acharya NV, Rosen AS, Polzer JP, DSouza DN, Perahia DG, Cavazzoni PA, Beasley CM, Baldessarini RJ  
**Duloxetine: meta-analysis of suicidal behaviors and thoughts in clinical trials for major depressive disorder**  
*Neuropsychopharmacol* 30:S1:S97; 2005.
4. Beasley CM, Sutton VK, Taylor C, Sethuraman G, Dossenbach M, Naber D, Pickar D  
**Does maintenance treatment with atypical antipsychotics worsen quality of life among stable patients with schizophrenia?**  
*Neuropsychopharmacol* 30:S1:S189; 2005.
5. Beasley C, Stauffer V, Liu-Seifert H, Rock S, Mitchell C, Dunayevich E, Davis J, Breier A  
**Overall treatment effectiveness as measured by time continuing on antipsychotic therapy**  
*Neuropsychopharmacol* 29:S1:S106; 2004.
6. Beasley CM, Sowell MO, Carlson C, Mukhnopadhyay N, Dannanberg j, Henry R, Breier A, Cavazzoni P  
**Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo**  
*Schizophrenia Res* 60:309, 2003.
7. Czekalla J, Beasley C, David S, Berg P, Stauffer V, Boylan C  
**Cardiac conduction in females under intramuscular (IM) and oral olanzapine from schizophrenia clinical trials ECGs**  
*Euro Neuropsychopharmacol* 12:S3:S291-292; 2002.
8. Tohen M, David RS, Beasley CM, Alaka K  
**QT intervals: IM olanzapine treatment in acutely agitated patients**  
*European Psychiatry* 17:105; 2002.
9. Beasley CM, Hamilton SH, Dossenbach M  
**Relapse prevention with olanzapine**  
*Schizophrenia Res* 41:196-197; 2000.
10. Czekalla J, Dellva MA, Berg PH, Grundy SL, Beasley CM  
**Cardiac safety profile of olanzapine based on preclinical and clinical ECG data**  
*Schizophrenia Res* 41:195; 2000.
11. Beasley CM, Hamilton SH, Dossenbach M  
**Relapse prevention with olanzapine**  
*Euro Neuropsychopharmacol* 10:304; 2000.
12. Tran PV, Basson BR, Kennedy JS, Beasley CM, Bymaster FP, Tollefson GD  
**The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone treatment in**

**patients with schizophrenia spectrum psychosis**

*Euro Neuropsychopharmacol* 9:290-291; 1999.

13. Schmidt M, Michelson D, Beasley CM, Kopp J, Koke S

**Long term treatment outcomes of highly anxious depressed patients: evidence from a 52-week trial with fluoxetine**

*Euro Neuropsychopharmacol* 9:209; 1999.

14. Wright P, Tollefson G, Beasley C, Tamura R, Tran P, Potvin J

**A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol**

*Schizophrenia Res* 29:206; 1998.

15. Jones B, Crawford A, Beasley C, Tollefson G

**The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration**

*Schizophrenia Res* 29:204-205; 1998.

16. Tamura R, Beasley C, Dellva M, Glazer W, Morgenstern H, Tollefson G

**What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?**

*Schizophrenia Res* 29:176; 1998.

17. Reams S, Sanger T, Beasley C

**Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders**

*Schizophrenia Res* 29:151-152, 1998.

18. Tran P, Lu Y, Sanger T, Beasley C, Tollefson G

**Olanzapine in the treatment of schizoaffective disorder**

*Schizophrenia Res* 29:151; 1998.

19. Beasley CM, Saylor ME, Kiesler GM, Potvin JH, Sanger TM, Tollefson GD

**The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia**

*Schizophrenia Res* 29:28; 1998.



20. Dellva M, Tamura R, Glazer W, Morgenstern H, Beasley C  
**What is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine?**  
*Euro Neuropsychopharmacol* 7:199-200; 1997.
21. Crawford A, Beasley C, Tollefson G  
**The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration**  
*Euro Neuropsychopharmacol* 7:199; 1997.
22. Crawford A, Gomez J, Beasley C, Tollefson G  
**Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial**  
*Euro Neuropsychopharmacol* 7:199; 1997.
23. Tran P, Dellva M, Rampey V, Tollefson G, Beasley C  
**Long-term continuation therapy with the novel antipsychotic olanzapine: a review of the clinical experience**  
*Euro Neuropsychopharmacol* 6:115; 1996.
24. Kuntz A, Tran P, Dellva M, Sanger T, Beasley C, Tollefson G  
**Acute phase efficacy and safety of olanzapine: a review**  
*Euro Neuropsychopharmacol* 6:115; 1996.
25. Dellva M, Satterlee W, Tran P, Beasley C, Greaney M, Tollefson G  
**Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute treatment**  
*Euro Neuropsychopharmacol* 6:106; 1996.
26. Lu Y, Sanger T, Beasley C, Tran P, Tollefson G  
**Olanzapine in the treatment of schizoaffective disorder**  
*European Neuropsychopharmacology* 6:106; 1996.
27. Tollefson G, Sanger T, Beasley C  
**The course of primary and secondary negative symptoms in a placebo- and comparator-controlled trial of the atypical antipsychotic olanzapine**  
*Euro Neuropsychopharmacol* 6:14; 1996.
28. Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A, Bradley P, Paul S  
**Olanzapine versus placebo, results of the United States double-blind olanzapine trial**  
*Euro Neuropsychopharmacol* 6:58; 1996.
29. Quicken FM, Stewart JW, McGrath PJ, Beasley C  
**Pattern analysis predicts relapse on fluoxetine and placebo during continuation**  
*Euro Neuropsychopharmacol* 6:153-154; 1996.
30. Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S, Van Ostrand R, Paul S  
**Acute and long-term results of the North American double-blind olanzapine trial**  
*Euro Neuropsychopharmacol* 6:59; 1996

31. Martin C, Genduso L, Revicki D, Hamilton S, Tran P, Beasley C  
**Quality of life outcomes of olanzapine, a new atypical antipsychotic agent**  
*Schizophrenia Res* 18:130-131; 1996.
32. Tollefson GD, Beasley CM, Tran PV, Tamura RN, Sanger TM, Wood A, Beuzen JN  
**Olanzapine versus haloperidol: results of the multi-center international trial**  
*Schizophrenia Res* 18:131; 1996.
33. Dittmann R, Beasley C, Geuppert M, Muhlenbacher  
**Clinical efficacy and safety of olanzapine: results from a double blind-multinational trial**  
*Pharmacopsychiatry* 28:172; 1995.
34. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W  
**Olanzapine: a promising “atypical” antipsychotic agent**  
*Schizophrenia Res* 15:169; 1995.
35. Saterlee W, Beasley C, Sanger T, Tollefson G  
**Additional clinical experiences with olanzapine an “atypical” antipsychotic**  
*Schizophrenia Res* 15:163; 1995.
36. Satterlee W, Beasley C, Sanger T, Tran P, Paul S, Tollefson G  
**Olanzapine a new “atypical” antipsychotic**  
*Schizophrenia Res* 15:163-164; 1995.
37. Tran PV, Beasley CM, Tollefson GD, Beuzen JN, Dellva MA, Sanger TM, Paul S  
**Acute and long-term results of the North American double-blind olanzapine trial**  
*Euro Neuropsychopharmacol* 5:347-348; 1995.
38. Amsterdam JD, Hornig-Rohan M, Rosenbaum JF, Quitkin FM, Fawcette J, Reimherr FW, Beasley CM  
**Fluoxetine and norfluoxetine levels in major depression**  
*Biological Psychiatry* 37:606; 1995.
39. Tollefson GD, Beasley CM, Tran PV, Sanger T  
**Olanzapine: a novel antipsychotic with broad spectrum profile**  
*Biological Psychiatry* 35:746-747; 1994.
40. Wood A, Beasley C, Tollefson G, Tran P  
**Efficacy of olanzapine in the positive and negative symptoms of schizophrenia**  
*Euro Neuropsychopharmacol* 4:224; 1994.
41. Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W  
**Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent**  
*Neuropsychopharmacol* 10:3S, Part 2:267S; 1994.
42. Beasley C, Tollefson G, Moore N, Tye N  
**Olanzapine: the new “atypical” antipsychotic agent**  
*Neuropsychopharmacol* 10:3S, Part 1:536S; 1994.

43. Bergstrom R, Beasley C, Levy N, Dubey A, Blumenfield M, Goodman A, Solomon R  
**Fluoxetine pharmacokinetics after daily doses of 20 mg fluoxetine in patients with severely impaired renal function**  
*Pharmaceutical Research* 8:S294; 1991.
44. Heiligenstein J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D  
**Fluoxetine not associated with violent behavior in controlled clinical trials**  
*Clinical Research* 39:768A; 1991.
45. Beasley C, Faries D, Saylor M, Potvin J  
**Fluoxetine not associated with suicidality in international controlled clinical trials in depression**  
*Clinical Research* 39:767A; 1991.

#### GRANT REPORTS

1. Anderson J, Kline P, Beasley C  
**A theory of the acquisition of cognitive skills**  
Technical Report 77-1. Yale University, 1978.
2. Anderson J, Kline P, Beasley C  
**Complex learning processes**  
Technical Report 78-1. Yale University, 1978.

Charles M. Beasley, Jr.

February 18, 2016